Stay updated on Surufatinib in Biliary Tract Carcinoma: Clinical Trial
Sign up to get notified when there's something new on the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page.

Latest updates to the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page
- Check6 days agoChange DetectedA banner about NIH website updates and a stated transition from “Artificial Intelligence” to “Super Intelligence” is no longer displayed.SummaryDifference1%

- Check13 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check27 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check34 days agoChange DetectedThe footer’s site revision number changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check48 days agoChange DetectedThe page now renders a 403 Forbidden error with the corresponding text and a Home button, indicating that access to the study record is blocked and the normal study details are not available.SummaryDifference0.5%

- Check55 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the full study details with an access-denied screen. The UI shows the error text and basic navigation (including Home and Revision: v3.7.0), while the substantive study information has been removed.SummaryDifference19%

Stay in the know with updates to Surufatinib in Biliary Tract Carcinoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page.